Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17184781 | 0.88 | CHRNB2 (0.43) | HRH3DYRK1ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL3800812 | 0.86 | PRMT6 (0.53) | PRMT6HRH3MAPTGSK3BDYRK1A | |
| SCHEMBL17108792 | 0.85 | ACHE (0.41) | HRH3DYRK1AALDH1A1FFAR1 | |
| SCHEMBL12316019 | 0.83 | PRMT6 (0.36) | PRMT6HRH3MAPTGSK3BDYRK1A | |
| SCHEMBL13362062 | 0.83 | GSK3B (0.37) | PRMT6HRH3MAPTGSK3BDYRK1A | |
| SCHEMBL3795067 | 0.83 | PSMB8 (0.44) | PRMT6GSK3BDYRK1ANCF1HTT | |
| SCHEMBL17686115 | 0.81 | CYP11B2 (0.46) | GSK3BCYP11B2FFAR1 | |
| SCHEMBL585841 | 0.80 | NCF1 (0.54) | HRH3SMN1; SMN2NCF1HTTALDH1A1 | |
| SCHEMBL146568 | 0.79 | HRH3 (0.56) | HRH3MAPTSMN1; SMN2HTTALDH1A1 | |
| Hydrochloric Acid SCHEMBL15845597 | 0.79 | NCF1 (0.52) | HRH3SMN1; SMN2NCF1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2025-04-01 | — | — | US | disclosed |
| CN-112135821-B | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | 方济各安吉利克化学联合股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | FACIT INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| US-11472795-B2 | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO—A.C.R.A.F. S.p.A. (IT) | 2022-10-18 | — | — | US | disclosed |
| EP-3423451-B1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | PROPELLON THERAPEUTICS INC (CA) | 2022-08-17 | — | — | EP | disclosed |
| CN-109195965-B | Inhibitors of WDR5 protein-protein binding | 普罗佩纶治疗公司 | 2022-07-26 | — | — | CN | disclosed |
| US-11319299-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2022-05-03 | — | — | US | disclosed |
| EP-3790873-B1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | ACRAF (IT) | 2022-04-27 | — | — | EP | disclosed |
| EP-3790873-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | Aziende Chimiche Riunite Angelini Francesco A.C.R. (IT) | 2021-03-17 | — | — | EP | disclosed |
| US-20210053956-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | AZIENDE CHIMICHE RIUNITE ANGLELINI FRANCESCO - A.C.R.A.F. S.p.A (IT) | 2021-02-25 | — | — | US | disclosed |
| US-8063071-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110212053-A1 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| US-20110212053-A1 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| US-20110212053-A1 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| EP-2303890-A2 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | Progenics Pharmaceuticals, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2009155527-A9 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2009155527-A2 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-06-04 | — | — | US | disclosed |
| EP-1896014-A2 | CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007005534-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319299-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | PRMT6 63/4885HRH3 1182/4885MAPT 2234/4885 |
| US-11472795-B2 | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | GSK3B, GSK3A, PYGB | PRMT6 3847/4885HRH3 2669/4885MAPT 480/4885 |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | PRMT6 63/4885HRH3 1182/4885MAPT 2234/4885 |
| US-20210053956-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | GSK3B, GSK3A, PYGB | PRMT6 3847/4885HRH3 2669/4885MAPT 480/4885 |
| US-20110212053-A1 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PIK3CA, AKT1, PIK3R5 | PRMT6 970/4885HRH3 1585/4885MAPT 3045/4885 |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | PRMT6 747/4885HRH3 568/4885MAPT 2603/4885 |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | WDR5, WDR82, WDR1 | PRMT6 63/4885HRH3 1182/4885MAPT 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.